Ablynx NV: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Ablynx NV and Algeta ASA Enter Into a Research Collaboration to Evaluate Potential of Alpha-Pharmaceuticals Comprising Thorium-277 Conjugated to Tumour-Targeting Nanobodies
Ablynx NV and Algeta ASA announced a research collaboration to evaluate a Targeted Thorium Conjugate (TTC) based on combining Algeta's thorium-227 alpha-pharmaceutical payload with Nanobodies generated using Ablynx's technology platform. Under the terms of the collaboration, Ablynx will provide access to Nanobodies against a specific, undisclosed target and Algeta will provide access to chelation and conjugation technologies, as well as to its alpha-emitter thorium-227. Both companies will contribute resources towards the collaboration, which is expected to last for up to a year initially with the option for extension thereafter. No further terms have been disclosed.
Latest Key Developments in Biotechnology
- Vermillion appoints James LaFrance as president and CEO
- Spectrum Pharmaceuticals Inc's Pivotal Trial of Captisol-Enabled (Propylene Glycol-Free) Melphalan Meets Primary Endpoint
- OncoGenex Pharmaceuticals Inc announces fast track designation granted for custirsen in combination with Cabazitaxel/Prednisone
- ReNeuron Group plc announces corporate update
- Share this
- Digg this